bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 2% – Time to Sell?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) shares traded down 2% on Monday . The company traded as low as $0.88 and last traded at $0.97. 173,044 shares were traded during trading, an increase of 23% from the average session volume of 140,314 shares. The stock had previously closed at $0.99.

bioAffinity Technologies Stock Down 2.4 %

The stock has a market capitalization of $14.81 million, a PE ratio of -1.16 and a beta of 2.85. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The business’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.73.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC purchased a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies as of its most recent filing with the Securities and Exchange Commission. 1.64% of the stock is owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.